Herceptin (trastuzumab) therapy during pregnancy: association with reversible anhydramnios

Obstet Gynecol. 2005 Mar;105(3):642-3. doi: 10.1097/01.AOG.0000141570.31218.2b.


Background: Herceptin (trastuzumab), a new a chemotherapeutic agent, is a monoclonal antibody that blocks the human epidermal growth factor receptor 2 protein. There is no reported experience with use of this agent during pregnancy and possible effects on the fetus.

Case: A patient with breast cancer was treated with Herceptin during pregnancy. This treatment was associated with anhydramnios, which resolved slowly after the drug was discontinued.

Conclusion: Although listed as a category B drug, experience with Herceptin in human pregnancy is limited, and it should be used with caution. Investigation of the role of human epidermal growth factor receptor 2 protein in the embryonic kidney may further our understanding of amniotic fluid dynamics.

Publication types

  • Case Reports

MeSH terms

  • Adult
  • Antibodies, Monoclonal / adverse effects
  • Antibodies, Monoclonal / therapeutic use*
  • Antibodies, Monoclonal, Humanized
  • Breast Neoplasms / drug therapy*
  • Carcinoma, Ductal, Breast / drug therapy*
  • Female
  • Humans
  • Infant, Newborn
  • Oligohydramnios / chemically induced*
  • Pregnancy
  • Pregnancy Complications, Neoplastic / drug therapy*
  • Trastuzumab


  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Trastuzumab